NASDAQ:ICPT Intercept Pharmaceuticals - ICPT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Intercept Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $13.59 -0.60 (-4.23%) (As of 03/22/2023 05:24 PM ET) Add Compare Share Share Today's Range$13.57▼$14.4150-Day Range$14.19▼$21.7152-Week Range$10.81▼$21.86Volume618,567 shsAverage Volume792,221 shsMarket Capitalization$566.30 millionP/E Ratio2.10Dividend YieldN/APrice Target$25.70 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Intercept Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside89.1% Upside$25.70 Price TargetShort InterestN/ADividend StrengthN/ASustainability-2.13Upright™ Environmental ScoreNews Sentiment0.86Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.60) to $0.25 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.56 out of 5 starsMedical Sector93rd out of 983 stocksPharmaceutical Preparations Industry30th out of 478 stocks 3.3 Analyst's Opinion Consensus RatingIntercept Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.70, Intercept Pharmaceuticals has a forecasted upside of 89.1% from its current price of $13.59.Amount of Analyst CoverageIntercept Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ICPT. Previous Next 0.0 Dividend Strength Dividend YieldIntercept Pharmaceuticals does not currently pay a dividend.Dividend GrowthIntercept Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIntercept Pharmaceuticals has received a 53.13% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Liver-disease medication (A05)", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Intercept Pharmaceuticals is -2.13. Previous Next 2.1 News and Social Media Coverage News SentimentIntercept Pharmaceuticals has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Intercept Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 7 people have searched for ICPT on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Intercept Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intercept Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders21.00% of the stock of Intercept Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.09% of the stock of Intercept Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Intercept Pharmaceuticals are expected to grow in the coming year, from ($1.60) to $0.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intercept Pharmaceuticals is 2.10, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.17.Price to Earnings Ratio vs. SectorThe P/E ratio of Intercept Pharmaceuticals is 2.10, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 92.33.Price to Book Value per Share RatioIntercept Pharmaceuticals has a P/B Ratio of 6.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Intercept Pharmaceuticals (NASDAQ:ICPT) StockIntercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in Morristown, NJ.Read More Receive ICPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ICPT Stock News HeadlinesMarch 17, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Raised by B. RileyMarch 13, 2023 | finance.yahoo.comIntercept (ICPT) Stock Down on FDA Committee Update on NDAMarch 22, 2023 | Investing Daily (Ad)Check Out This 6-Year Win StreakDespite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. March 13, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Intercept Pharma (ICPT) and Takeda Pharmaceutical Company (TAK)March 12, 2023 | americanbankingnews.comIntercept Pharmaceuticals (NASDAQ:ICPT) Shares Down 7.3% March 11, 2023 | finance.yahoo.comIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) down to US$672m market cap, but institutional owners may not be as affected after a year of 8.0% returnsMarch 10, 2023 | finance.yahoo.comIntercept Announces FDA Advisory Committee Meeting Date for Obeticholic Acid as a Treatment for Pre-Cirrhotic Liver Fibrosis due to NASHMarch 10, 2023 | marketwatch.comIntercept Says FDA Sets AdCom Meeting on Obeticholic Acid >ICPTMarch 22, 2023 | Investing Daily (Ad)Check Out This 6-Year Win StreakDespite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. March 10, 2023 | markets.businessinsider.comJMP Securities Keeps Their Hold Rating on Intercept Pharma (ICPT)March 10, 2023 | msn.comHeres Why Intercept (ICPT) Stock is Up 28.7% in 3 MonthsMarch 9, 2023 | finance.yahoo.comIntercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Barclays Global Healthcare Conference March 14, 2023March 3, 2023 | finance.yahoo.comIntercept (ICPT) Q4 Earnings Beat, Ocaliva Sales IncreaseMarch 3, 2023 | finance.yahoo.comQ4 2022 Intercept Pharmaceuticals Inc Earnings CallMarch 2, 2023 | markets.businessinsider.comB.Riley Financial Keeps Their Buy Rating on Intercept Pharma (ICPT)March 2, 2023 | finance.yahoo.comIntercept Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates; Issues 2023 Financial GuidanceMarch 1, 2023 | msn.comPreview: Intercept Pharmaceuticals's EarningsFebruary 23, 2023 | finance.yahoo.comIntercept to Announce Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023February 13, 2023 | finance.yahoo.comInside the NASH drug boom: New drugs for a ‘silent’ liver disease that affects millions near FDA approvalJanuary 24, 2023 | seekingalpha.comIntercept: Huge Potential Upsides With Binary Catalyst UnlockingJanuary 20, 2023 | finance.yahoo.comDoes Intercept (ICPT) Have the Potential to Rally 52.08% as Wall Street Analysts Expect?January 19, 2023 | finance.yahoo.comFDA Accepts Intercept’s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASHJanuary 13, 2023 | finance.yahoo.comIntercept (ICPT) Gains 12.4% in the Past Six Months: Here's WhyJanuary 5, 2023 | finance.yahoo.comIntercept Pharmaceuticals to Present at J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023January 4, 2023 | finance.yahoo.comIntercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023December 23, 2022 | marketwatch.comIntercept Pharmaceuticals Resubmits New Drug Application for Obeticholic AcidDecember 23, 2022 | finance.yahoo.comIntercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASHSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ICPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ICPT Company Calendar Last Earnings11/03/2021Today3/22/2023Next Earnings (Estimated)5/05/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ICPT CUSIP45845P10 CIK1270073 Webwww.interceptpharma.com Phone(646) 747-1000Fax646-747-1001Employees437Year FoundedN/APrice Target and Rating Average Stock Price Forecast$25.70 High Stock Price Forecast$49.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+81.1%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$6.47 Trailing P/E Ratio2.19 Forward P/E RatioN/A P/E GrowthN/ANet Income$221.82 million Net Margins70.39% Pretax Margin-61.20% Return on EquityN/A Return on Assets-30.11% Debt Debt-to-Equity Ratio2.40 Current Ratio2.35 Quick Ratio2.35 Sales & Book Value Annual Sales$285.71 million Price / Sales2.07 Cash FlowN/A Price / Cash FlowN/A Book Value$2.25 per share Price / Book6.31Miscellaneous Outstanding Shares41,670,000Free Float32,919,000Market Cap$591.30 million OptionableOptionable Beta1.29 Key ExecutivesJerome B. DursoPresident, Chief Executive Officer & DirectorBryan BallChief Quality Officer & Senior VP-OperationsAndrew SaikChief Financial OfficerM. Michelle BerreyChief Medical OfficerLinda M. RichardsonChief Commercial Officer & Executive VPKey CompetitorsInnovivaNASDAQ:INVAEmergent BioSolutionsNYSE:EBSLexicon PharmaceuticalsNASDAQ:LXRXImmunoGenNASDAQ:IMGNVanda PharmaceuticalsNASDAQ:VNDAView All CompetitorsInstitutional OwnershipParallax Volatility Advisers L.P.Sold 23,000 shares on 2/27/2023Ownership: 0.000%NatixisBought 3,998 shares on 2/24/2023Ownership: 0.010%Macquarie Group Ltd.Bought 16,055 shares on 2/21/2023Ownership: 1.622%Alliancebernstein L.P.Bought 7,600 shares on 2/16/2023Ownership: 0.077%State of WyomingBought 2,042 shares on 2/16/2023Ownership: 0.005%View All Institutional Transactions ICPT Stock - Frequently Asked Questions Should I buy or sell Intercept Pharmaceuticals stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ICPT shares. View ICPT analyst ratings or view top-rated stocks. What is Intercept Pharmaceuticals' stock price forecast for 2023? 7 equities research analysts have issued 1-year target prices for Intercept Pharmaceuticals' stock. Their ICPT share price forecasts range from $14.00 to $49.00. On average, they expect the company's share price to reach $25.70 in the next year. This suggests a possible upside of 81.1% from the stock's current price. View analysts price targets for ICPT or view top-rated stocks among Wall Street analysts. How have ICPT shares performed in 2023? Intercept Pharmaceuticals' stock was trading at $12.37 at the start of the year. Since then, ICPT stock has increased by 14.7% and is now trading at $14.19. View the best growth stocks for 2023 here. When is Intercept Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023. View our ICPT earnings forecast. How were Intercept Pharmaceuticals' earnings last quarter? Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($1.00) by $0.89. The biopharmaceutical company had revenue of $92.80 million for the quarter, compared to the consensus estimate of $83.04 million. The firm's revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the firm posted ($2.01) EPS. What ETFs hold Intercept Pharmaceuticals' stock? ETFs with the largest weight of Intercept Pharmaceuticals (NASDAQ:ICPT) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Invesco Nasdaq Future Gen 200 ETF (QQQS), Direxion Daily S&P Biotech Bull 3x Shares (LABU), ALPS Medical Breakthroughs ETF (SBIO), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB). What guidance has Intercept Pharmaceuticals issued on next quarter's earnings? Intercept Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, March, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $310.00 million-$340.00 million, compared to the consensus revenue estimate of $321.92 million. What is Mark Pruzanski's approval rating as Intercept Pharmaceuticals' CEO? 32 employees have rated Intercept Pharmaceuticals Chief Executive Officer Mark Pruzanski on Glassdoor.com. Mark Pruzanski has an approval rating of 80% among the company's employees. What other stocks do shareholders of Intercept Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib). What is Intercept Pharmaceuticals' stock symbol? Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT." Who are Intercept Pharmaceuticals' major shareholders? Intercept Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (2.36%), Renaissance Technologies LLC (1.71%), Macquarie Group Ltd. (1.62%), Geode Capital Management LLC (1.41%), ExodusPoint Capital Management LP (1.28%) and Jupiter Asset Management Ltd. (1.02%). Insiders that own company stock include Christian Weyer, David A Ford, Jason Campagna, Paolo Fundaro, Sandip Kapadia, SPA Genextra and Srinivas Akkaraju. View institutional ownership trends. How do I buy shares of Intercept Pharmaceuticals? Shares of ICPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Intercept Pharmaceuticals' stock price today? One share of ICPT stock can currently be purchased for approximately $14.19. How much money does Intercept Pharmaceuticals make? Intercept Pharmaceuticals (NASDAQ:ICPT) has a market capitalization of $591.30 million and generates $285.71 million in revenue each year. The biopharmaceutical company earns $221.82 million in net income (profit) each year or $6.47 on an earnings per share basis. How many employees does Intercept Pharmaceuticals have? The company employs 437 workers across the globe. How can I contact Intercept Pharmaceuticals? Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The official website for the company is www.interceptpharma.com. The biopharmaceutical company can be reached via phone at (646) 747-1000, via email at investors@interceptpharma.com, or via fax at 646-747-1001. This page (NASDAQ:ICPT) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.